Company Shanghai Rightongene Biotechnology Co., Ltd.

Equities

688217

CNE100005212

Medical Equipment, Supplies & Distribution

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Ratings for Shanghai Rightongene Biotechnology Co., Ltd.

EPS Revisions

Annual profits - Rate of surprise

Sector Diagnostic & Testing Substances

SHANGHAI RIGHTONGENE BIOTECHNOLOGY CO., LTD.

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
24.98 ^CNY	+1.13%		-6.09%	-30.18%

Apr. 26	Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 29	Shanghai Rightongene Biotechnology Co., Ltd. commences an Equity Buyback Plan for CNY 20 million worth of its shares, under the authorization approved on February 28, 2024.	CI

Shanghai Rightongene Biotechnology Co Ltd is a China-based company principally engaged in the research and development, production and sales of in-vitro diagnostic products, as well as the provision of scientific research and testing services. The Company's main products include leukemia molecular diagnostic kits and lymphoma molecular diagnostic kits. The Company mainly provides precise gene and antigen testing services for patients with blood diseases, solid tumors and infectious diseases. The Company also provides scientific research services applied in basic research, disease typing, drug adaptability and target genetic testing. The Company mainly conducts its businesses within domestic market.

Number of employees: 501

CNY in Million	2022	Weight	2023	Weight	Delta
Self-produced Reagents 81.5 %	182	42.9 %	210	81.5 %	+15.46%
Testing Services 9.1 %	221	52.0 %	23	9.1 %	-89.36%
Other Business 4.7 %	8	1.9 %	12	4.7 %	+47.51%
Scientific Research Services 2.4 %	9	2.0 %	6	2.4 %	-29.00%
Purchased Reagents 2.3 %	4	1.0 %	6	2.3 %	+36.58%

CNY in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	424	100.0 %	258	100.0 %	-39.14%

Managers	Title	Age	Since
Hui Xiong CEO	Chief Executive Officer	52	12-02-16
Yan Li DFI	Director of Finance/CFO	42	20-03-26
Jun Xiong BRD	Director/Board Member	48	14-12-31
Ming Fan IRC	Investor Relations Contact	29	23-03-09

Members of the board	Title	Age	Since
Xue Wei Yuan BRD	Director/Board Member	52	18-12-12
Gui Ying Zhao BRD	Director/Board Member	70	18-12-12
Guang Ce Jiang BRD	Director/Board Member	53	23-08-23
Hui Xiong CEO	Chief Executive Officer	52	12-02-16
Shang Xian Gao BRD	Director/Board Member	67	18-12-12
Jun Xiong BRD	Director/Board Member	48	14-12-31
Ze Gao BRD	Director/Board Member	39	19-05-12
Yun Hang Li CHM	Chairman	36	16-01-31
Liang Ying Cheng BRD	Director/Board Member	50	23-05-14
Yan Bo Sun BRD	Director/Board Member	38	22-12-15

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	55,855,896	30,543,755 ( 54.68 %)	0	54.68 %

Name	Equities	%	Valuation
Orient Securities Asset Management Co. Ltd. 2.400 %	881,572	2.400 %	3 M ¥
Da Cheng Fund Management Co., Ltd. 0.9472 %	347,947	0.9472 %	1 M ¥
Huatai-PineBridge Fund Management Co., Ltd. 0.9034 %	331,845	0.9034 %	1 M ¥
Yinhua Fund Management Co., Ltd. 0.7272 %	267,124	0.7272 %	953 553 ¥
ICBC Credit Suisse Asset Management Co., Ltd. 0.6806 %	250,000	0.6806 %	892 425 ¥
GF Fund Management Co., Ltd. 0.3272 %	120,200	0.3272 %	429 078 ¥
Zhong Ou Asset Management Co., Ltd 0.1527 %	56,103	0.1527 %	200 271 ¥
Dongxing Asset Management Co. Ltd. 0.1141 %	41,916	0.1141 %	149 628 ¥
Hongde Fund Management Co., Ltd. 0.0372 %	13,667	0.0372 %	48 787 ¥
Bosera Asset Management Co., Ltd. 0.0305 %	11,200	0.0305 %	39 981 ¥

Shanghai Rightongene Biotechnology Co., Ltd.

147 Lane 1817, Huifeng West Road Fengxian District

201403, Shanghai

http://www.rightongene.com

address Shanghai Rightongene Biotechnology Co., Ltd.(688217)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.98

Average target price

Consensus

Estimates Revisions

Company calendar

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Diagnostic & Testing Substances

	1st Jan change	Capi.
SHANGHAI RIGHTONGENE BIOTECHNOLOGY CO., LTD.	-30.18%	191M
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-1.52%	8.37B
DIASORIN S.P.A.	+10.68%	5.84B
LANTHEUS HOLDINGS, INC.	+26.94%	5.4B
AUTOBIO DIAGNOSTICS CO., LTD.	-5.09%	4.37B
10X GENOMICS, INC.	-52.54%	3.23B
ANDON HEALTH CO., LTD.	+14.18%	2.8B
MYRIAD GENETICS, INC.	+32.50%	2.26B
VITROLIFE AB	-6.47%	2.22B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-1.69%	1.87B

Diagnostic & Testing Substances